
OFFICE OF NEW ANIMAL DRUG EVALUATION REVIEWER'S CHAPTER

**MEMORANDUM RECOMMENDING APPROVAL (MRA) FOR ORIGINAL AND
SUPPLEMENTAL (ABBREVIATED) NEW ANIMAL DRUG APPLICATIONS ((A)NADA)**

I.	Purpose	1
II.	Purpose of an MRA.....	1
III.	Who prepares the MRA using the office template?.....	1
IV.	General instructions for using the office template MRA	2
V.	References.....	10
VI.	Version history.....	11

I. PURPOSE

This document provides instructions on how to use the Office of New Animal Drug Evaluation's template to prepare a Memorandum Recommending Approval (MRA) for an original or B1 supplemental (abbreviated) new animal drug application ((A)NADA). An MRA should always be part of the approval package for an (A)NADA.^{1, 2, 3}

II. PURPOSE OF AN MRA

An MRA briefs the individuals signing the approval (i.e., the center director, office director) on the basis for our recommendation to approve an (A)NADA. The MRA incorporates by reference the data, information, and reviews that support our recommendation. The Office of New Animal Drug Evaluation (ONADE) prepares an MRA as part of the final action package for the approval of an original (A)NADA. In addition, ONADE prepares an MRA for supplemental NADA approvals that includes safety and/or effectiveness data (B1 supplements).⁴ If you have questions about which applications need an MRA, consult your team leader.

III. WHO PREPARES THE MRA USING THE OFFICE TEMPLATE?

The MRA is prepared by the reviewer, consumer safety officer (CSO), or other individual designated by the division to prepare the approval package for an application. If the reviewer has questions about who prepares the MRA, they should consult with their team leader or division director.

Team leaders and division directors are responsible for ensuring that the correct version of the office template was used to create the (A)NADA MRA and confirming the accuracy of the dates and submission codes referenced in the MRA.

¹ See P&P 1243.3800

² This P&P does not apply to (A) NADAs for Animal Drug Availability Act feed combinations.

³ This P&P does not apply to manufacturing supplements, minor labeling supplements (NFs and NLs) or conditional approvals. See P&P 1243.6020 and 1243.6030 for information on minor labeling supplements.

⁴ Supplemental ANADA approvals (outside of NF and NL labeling supplements) are very rare and are not covered in this P&P.

IV. GENERAL INSTRUCTIONS FOR USING THE OFFICE TEMPLATE MRA

Use the appropriate ONADE MRA template located on the ONADE Template Page in SharePoint. If you have questions about which MRA template to use, consult your team leader. This section describes the contents of each section of the MRA in more detail than the template. Refer to this section as you use the MRA template.

A. General Instructions for Using the MRA Template:

1. Certain template boilerplate text is contained in shaded fill-in text fields or drop-down menus. Choose the appropriate information relating to your specific application. If none of the templated text is applicable, the fill-in or drop-down can be deleted and the text can be entered.
2. Words in brackets or italics may provide instruction, describe the information you are to provide, or give examples of the type of information that you are to include in a particular portion of the MRA.
3. Where you see brackets, italics, shaded areas or text fields, provide information relating to your specific application.
4. Based on the type of application, select the appropriate boilerplate language for each section in the template.
5. Include all sections and subsections of the MRA (unless a comment bubble specifically allows for deletion of a (sub)section identified in the template. For each section, include the boilerplate language or appropriate information described in the (A)NADA MRA template.
6. The header will appear on all pages (except the first page) of the MRA template. Double click in the header to insert the Submission Tracking and Reporting System information (i.e., (A)NADA number and submission ID, and subclass code) in place of <A/N-000000-X-0000-XX>.
7. When writing the proprietary name, use the appropriate trademark symbols (i.e., ® or ™). See P&P 1243.3015 Proprietary Names for information on how to format the proprietary name.

B. The “To” Line of the MRA

1. Original (A)NADA approvals

Address the MRA to the Center Director, through the Director, ONADE.

2. Supplemental NADA approvals

You will address most MRAs for supplemental approvals to the Director, ONADE, through the appropriate division director, except for supplements that would approve a new species, significant new indications, or change in Rx/OTC

status, which will be addressed to the Center Director, through the Director, ONADE.⁵

C. General Information Table

The MRA's General Information table should be identical in all aspects to the General Information table in the FOI Summary, except the INAD number will not appear in the FOI Summary.⁶

1. File Number

Insert the (A)NADA application number and, if applicable, the INAD number.

2. Sponsor, their address, Drug Labeler Code, and U.S. Agent⁷

If this is not the first approval for a sponsor, copy the sponsor name, address, and drug labeler code exactly as it appears in 21 CFR 510.600(c). Do not copy the sponsor address provided in eSubmitter in this section. Use the listing in the electronic CFR to obtain the most recent information.⁸ If this is a sponsor's first approval, see your team leader for assistance.

If the sponsor does not reside or have a place of business within the U.S., insert the name and address of the authorized U.S. agent provided in "U.S. Agent/U.S. Employee Information" section in eSubmitter.⁹ Delete the U.S. agent field if not applicable.

3. Proprietary Name(s)

The proprietary name is the exclusive name the sponsor assigns to the approved drug product. It is commonly known as the tradename and may include trademarked and non-trademarked words. The proprietary name should match the product labeling. Use the proprietary name consistently throughout the MRA. Format the proprietary name as described in P&P 1243.3015.

⁵ Note: If there is uncertainty about who the approver/signer of a supplemental approval should be, the division director or team leader should always speak with the ONADE Office Director.

⁶ Note: For NADA applications under the Division of Animal Bioengineering and Cellular Therapies (DABCT), the sections may be modified based on the type of products. The reviewer or preparer should consult with the DABCT team leader or division director for more information.

⁷ See P&P 1243.2020 on U.S agents

⁸ The electronic CFR (e-CFR) provides the most up to date information. It is a different site than the online CFR, which is an electronic copy of the most recent printed CFR (issued in April of each year).

⁹ 21 CFR §514.1(a).

4. Drug Product Established Name(s)¹⁰

The drug product established name is the non-proprietary name of the drug product and may or may not include the route of administration and dosage form. To identify the drug product established name, refer to the product labeling.¹¹ The established name is typically presented within parenthesis under the proprietary name. Some examples include "(carprofen tablets)" and "(mebendazole oral suspension)". There may be exceptions, such as "(cyclosporine capsules) USP MODIFIED." Use the drug product established name consistently throughout the MRA.

5. Pharmacological Category

This section describes the action of the drug product (e.g., anticomicrobial, antimicrobial, or antiparasitic). Include the schedule if this is a controlled substance.

6. Dosage Form(s)

Include the dosage form(s) even if it is part of the proprietary name or drug product established name.

The dosage form refers to the physical description of the approved manufactured product. For example, aerosol, capsule, cream, emulsion, gel, granule, implant, paste, soluble powder, suspension, or Type A medicated article. For additional dosage form examples, consult Appendix I of Guidance for Industry (GFI) #191¹² and the dosage form worksheet.¹³

7. Amount of Active Ingredient(s)

This section describes the amount of drug(s) per tablet, mL, percentage, or other measure of concentration. The amount should be expressed exactly as on product labeling, which may be on the basis of the active moiety, the active ingredient, or both.

¹⁰ ONADE Policy: Drug Product Established Name for New Animal Drugs at
Internal information redacted

¹¹ In some cases, the product established name as written on the labeling may be inconsistent. In these cases, refer to the drug established name P&P or discuss with your team leader.

¹² GFI #191, Changes to Approved NADAs – New NADAs vs. Category II Supplemental NADAs
(<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-191-changes-approved-nadas-new-nadas-vs-category-ii-supplemental-nadas>)

¹³ Internal information redacted

8. How Supplied

This section describes the size and description of the containers (e.g., 50- and 100-mL vials, 50-lb bag). This information should be expressed exactly as on product labeling.

9. Dispensing Status

This section identifies whether the marketing status is by prescription (Rx), over-the-counter (OTC), or veterinary feed directive (VFD).

10. Dosage Regimen

This section describes the approved dose, frequency, and duration of treatment as printed on the approved labeling. Detailed dosage and administration information from the product insert (e.g., dosing tables provided for the convenience of calculating dosage) should not reside here; however, wording included in this section should match the wording on the approved labeling. Tables that provide information on different doses by weight bands, clarifying the amount of new animal drug to give or apply when there are multiple concentrations or tablet sizes/strengths approved for the new animal drug, can be included here.

11. Route(s) of Administration

This section describes how the product is administered.¹⁴ For example, transdermal, immersion, infiltration, inhalation, intradermal, intramuscular, intramammary, ocular, oral, otic, or topical. For additional examples of routes of administration, consult Appendix II of GFI #191 and the route of administration worksheet.¹⁵

12. Species/Class(es)

This section should identify the target animal species to which the approval applies exactly as stated on product labeling in the "Indications" section. Some approvals apply to a specific class(es) within a species (e.g., lactating dairy cows). If there is a specific class(es) for the approval, include that information here. If there is no class limitation, enter the species in plain language (e.g., cattle rather than bovine, dogs rather than canine). For supplemental

¹⁴ For an original approval, list all information. For supplemental NADAs, abbreviate the information to include only that to which the supplement applies, unless the currently approved information is needed to provide context. If you include all of the previously approved information with the new or modified information, then highlight (by bolding) the new or modified information so that the new or modified information is readily distinguishable.

¹⁵ Internal information redacted

approvals, only list the species for which the supplement is approved. For additional examples of classes of major food animals, consult Appendix III of GFI #191.

13. Indication(s)

In this section, include any new indication(s) we are approving. If no new indication is being approved, include only the indication(s) impacted by the supplemental approval or indication(s) necessary to provide context for the supplemental approval. (Examples: for an approval with multiple species, if the approval is for a reduced withdrawal period for swine, include only the swine indication(s). For an approval adding a new pathogen to an approved indication, include the complete indication with all previously approved pathogens and the added pathogen.) Indication(s) should always be provided, even for supplemental approvals that do not change any existing indications, so readers will know what indication(s) the approval applies to.

Copy the indication(s) verbatim from the indication(s) section of the package insert. If there isn't a package insert copy it from the immediate container's carton labeling or the immediate container label. If the proprietary name appears in the indication, format the name the same way the proprietary name is formatted elsewhere in the approval package; i.e., if the indications section of the package insert does not use the trademark symbol for the drug ([®], [™]), still include it here for consistency across documents

14. Effect(s) of Supplement (NADA only)

If this is a supplemental approval, this section should briefly describe the changes we are approving. For original approvals, delete this row from the General Information section.

15. Reference Listed New Animal Drug (ANADA only)

Provide the RLNAD proprietary name, drug product established name, (A)NADA number and sponsor name as indicated in the template.

D. Suitability Petition (ANADA only)

Suitability petitions (SP) allow sponsors of generic new animal drugs to request permission to submit an ANADA for a generic that differs from the RLNAD in specific ways, as defined under section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act. The permissible differences include:

- route of administration,
- dosage form, strength (concentration),
- a change in one active ingredient in a combination drug, and
- a change in one Type A medicated article in a feed-use combination.

To approve a SP, the proposed change should not require the petitioner to conduct investigations to demonstrate the safety or effectiveness of the generic new animal drug for its intended uses.

If the generic drug product is the subject of an approved SP, provide the information requested in the template for this section.

E. Effectiveness (NADA only)

This section identifies the submission/review document(s) and technical section complete letters (if applicable) that contain the effectiveness data pertinent to this approval. If necessary, include additional effectiveness information unique to the application. For supplemental NADAs that do not contain new effectiveness studies, use the boilerplate language in the template.

F. Target Animal Safety (NADA only)

This section identifies the submission/review document(s) and technical section complete letters (if applicable) that contain the safety data pertinent to this approval. If necessary, include additional target animal safety information unique to the application. For supplemental NADAs that do not contain new target animal safety studies, use the boilerplate language in the template.

G. Bioequivalence (ANADA only)

This section identifies the submission/review document(s) and technical section complete letter (if applicable) that contain the bioequivalence data pertinent to this approval. If a waiver from the requirement to demonstrate *in vivo* bioequivalence (biowaiver) was granted, provide that information using the first paragraph in the MRA template. If an *in vivo* bioequivalence study was performed, provide the appropriate information as outlined in the second paragraph of the MRA template.

H. Human Food Safety

This section identifies the submission/review document(s) and technical section complete letters (if applicable) that contain the safety data pertinent to this approval. If necessary, include additional human food safety information unique to the application.

If the product is for use in non-food producing animal species, then include the standard language in the template explaining that we did not require human food safety data. For approvals that result in a tolerance change for an approved drug, the preparer should document in the MRA that an email was sent to the Office of Surveillance and Compliance.¹⁶

¹⁶ See P&P 1243.3760 for drug tolerance notification process

I. Chemistry, Manufacturing Methods, and Controls

This section identifies the submission/review document(s) and technical section complete letters (if applicable) that contain the chemistry and manufacturing data pertinent to the approval and also documents the current GMP compliance status of the drug manufacturing facility. For all the original applications the expiration date of the approved drug should also be documented. If a supplemental approval did not include a change in expiration dating, it should be documented as "Not applicable". See P&P 1243.3800 for information on how to perform cGMP status checks for approvals

J. Environmental Impact

This section identifies the reviews, technical section complete letters (if applicable), environmental information in the end-game meeting memo (if applicable), and any other environmental review documents [e.g., finding of no significant impact (FONSI)] (if applicable). Also include the appropriate boilerplate language for accepting a claim of categorical exclusion, preparation of an environmental assessment and FONSI, or preparation of an environmental impact statement and record of decision.

K. Freedom of Information Summary

Include the boilerplate language provided in the MRA template. If applicable reference the reviews and letters that are relevant to the application.

L. Labeling

This section identifies the submission/reviews and technical section complete letters (if applicable) that contain the approved labeling information. If the labeling needs to be updated due to typographical errors, that information should be included in this section.

M. All Other Information (AOI) (NADA only)

This section identifies the submission/reviews and technical section complete letters (if applicable) that contain the sponsor's affirmative statement that there is no AOI that are applicable to this submission. If the sponsor provides an affirmative statement via email, the preparer should reference the email in this section and include a copy of the email in the approval package.

N. Special Concurrence

For most approvals include the boilerplate language "None" from the template. If the approval required communication between the ONADE Policy Team and Office of Chief Council on legal issues, consult with the ONADE Policy Team for the verbiage to be included in this section.

O. Bioresearch Monitoring Status

Document the BIMO status check in this section. If there are issues associated with the status check consult with your team leader. See P&P 1243.3800 for information on how to perform status checks for approvals

P. Drug Experience Report (DER) Status

This section is where we include information provided by the individual who reviewed the adverse drug experience/event history for the approved drug product report. If the DER is reviewed by the Division of Surveillance reference the email confirmation in this section. If necessary, add any additional information for further clarification of the DER report. See P&P 1243.3800 for information on how to perform status check approvals.

Q. Supplemental Applications (NADA only)

For supplemental approvals, include the boilerplate language in the MRA to state whether there was a need for the reevaluation of the safety and effectiveness data in the original NADA. For original approvals, delete the boilerplate language and insert "Not applicable".

R. Patent Term (NADA only) or Patent Certification (ANADA only)

NADA: This section identifies any relevant patents and the expiration date for each patent that was provided by the sponsor in the application or in the labeling technical section. If the sponsor provides an affirmative statement in the application stating that there is no patent information include the boilerplate language in the template. If the sponsor provides an affirmative statement via email, the preparer should reference the email in this section and include a copy of the email in the approval package.

ANADA: This section identifies any relevant RLNAD patents and the expiration date for each patent. Choose the appropriate patent certification information in the MRA template. The template contains boilerplate language documenting that the reviewer confirmed the patent information provided by the sponsor with what is listed in the Green Book on Animal Drugs @ FDA.

S. Exclusivity (NADA only) or Marketing Exclusivity (ANADA only)

NADA: This section contains information on whether marketing exclusivity was granted or not to the sponsor. Include the appropriate boilerplate language provided in the MRA template. The boilerplate language explains why we have or have not granted exclusivity. In some cases, the boilerplate language in the MRA template may not be appropriate; in such a case see P&P 1243.5780 for additional language or if necessary, contact the ONADE Policy Team.

ANADA: This section contains information on whether there are any unexpired marketing exclusivity periods listed for the RLNAD. Include the appropriate boilerplate language provided in the MRA template. The template includes

boilerplate language to describe any RLNAD indications protected by marketing exclusivity (if applicable).

T. Regulation

This section contains information on the draft regulation amending the animal drug regulations (Title 21 of the Code of Federal Regulations) to reflect the supplemental or original approval. Use the appropriate boilerplate language provided in the MRA template.

U. Communication Staff Notification

This section provides information on whether the division has or has not sent advance notification of the upcoming approval to the communication staff (FDA's Office of External Affairs and the Strategic Communications and Public Engagement Staff). See P&P 1243.3800 to follow the instructions for the notification process.

V. Citizen's Petition Status

The preparer should reference the confirmatory email from the Policy and Regulations Staff in this section and include it in the approval package. In cases where the approval has an impact on an existing citizen's petition, the preparer should consult with their team leader or division director to determine the appropriate boilerplate language to include in this section.

W. Recommendation

Include the boilerplate language provided in the MRA template to confirm that all the technical sections are complete and support the approval of the application.

V. REFERENCES

§ 510.600, Names, addresses, and drug labeler codes of sponsors of approved applications

§ 514.1, Applications

GFI #191, Changes to Approved NADAs – New NADAs vs. Category II Supplemental NADAs

CVM Program Policies and Procedure Manual

1240.2325 – CVM Guidance on Media Inquiries

CVM Program Policies and Procedure Manual – ONADE Reviewer's Chapter

1243.3015 – Proprietary Names

1243.3760 – Drug Tolerance Notification Process

1243.3800 – Reviewing, Preparing and Routing of Approval Packages for Certain Abbreviated and New Animal Drug Applications

1243.5761 – Freedom of Information Summary (FOI) for Original and Supplemental New Animal Drug Applications (NADA)

1243.5780 - Exclusivity and Exclusive Marketing Rights Boilerplate Language for Use in the Following Documents: Memorandum Recommending Approval, Letter to Applicant, and Freedom of Information Summary

1243.6020 – Review of New Animal Drug Application and Abbreviated New Animal Drug Application Supplements (NL Subclass)

1243.6030 – Review of Labeling Changes in Manufacturing Supplements

1243.8220 – Requesting a Bioresearch Monitoring (BIMO) Status Check

Beta Test Dosage Forms Detailed Worksheet

Beta Test Route of Administration (ROA) Worksheet

VI. VERSION HISTORY

August 31, 2016 – Original version.

August 28, 2019 – Removed section on distribution copies of the MRA and filing paper copies of the MRA as this is no longer current practice. Revised also to include reference to the proprietary names P&P and information about speaking the ONADE director if there is any uncertainty about who should sign the approval package for the addition of a new indication. Updated the format to the current format for ONADE P&Ps.

November 2, 2020- Updated to add information on all the sections in the MRA template for NADA and ANADA approvals.

January 26, 2021 – Minor edits to fix typographical errors and errors in the titles of some references.

February 17, 2021 – Updated to remove the line that says to send an email to the Environmental Team in the Environmental Impact section J.